Pandia Health Clinical Gaps and Limitations: What They Miss

What Pandia Health Actually Offers

Pandia Health operates as a direct-to-consumer telehealth service prescribing hormonal contraceptives and a limited menu of menopause therapies. Patients complete an online intake questionnaire, a physician reviews it asynchronously, and prescriptions ship to the patient's door. The model removes a common barrier: the in-office visit requirement that the American College of Obstetricians and Gynecologists (ACOG) has acknowledged delays contraceptive access for millions of women [1].

The platform prescribes combined oral contraceptives (COCs), progestin-only pills, the transdermal patch (Xulane), and the vaginal ring (NuvaRing/Annovera). That covers a meaningful slice of the contraceptive market. But the CDC's U.S. Selected Practice Recommendations identify over a dozen distinct contraceptive methods, and Pandia's formulary excludes the most effective ones: the copper IUD (99.2% typical-use efficacy), the levonorgestrel IUD (99.8%), and the etonogestrel implant (99.95%) [2]. These long-acting reversible contraceptives (LARCs) require in-person placement, which a mail-order platform cannot provide. That is not a criticism of Pandia's intentions. It is a structural limitation worth understanding before you choose a provider.

The Asynchronous Care Model and Its Trade-Offs

Most Pandia consultations happen without a live conversation. You fill out a form. A doctor reviews it. This is efficient, but it is not a clinical encounter in the traditional sense.

The ACOG Committee Opinion on telehealth and contraception notes that synchronous video visits allow clinicians to assess affect, ask follow-up questions in real time, and catch inconsistencies in patient-reported history [1]. A 2021 review in Contraception found that asynchronous prescribing platforms had lower rates of documented contraindication screening compared to synchronous telehealth or in-person visits [3]. The difference was not enormous (88% vs. 94% screening completion), but for a category where missed contraindications can mean venous thromboembolism (VTE), even small gaps carry clinical weight.

Blood pressure measurement is one concrete example. The WHO Medical Eligibility Criteria for Contraceptive Use classify uncontrolled hypertension (systolic ≥160 mmHg) as a Category 4 contraindication for combined hormonal contraceptives, meaning the method should not be used [4]. Pandia asks patients to self-report their blood pressure. A 2019 study in the Journal of the American Heart Association found that 46% of adults with hypertension were unaware of their condition [5]. Asking an undiagnosed hypertensive patient whether they have high blood pressure produces a predictable answer. It will be wrong.

Venous Thromboembolism Risk: The Screening Gap

Combined hormonal contraceptives increase VTE risk by 3- to 4-fold over baseline, from roughly 1-2 per 10,000 woman-years to 3-9 per 10,000 woman-years depending on the progestin type [6]. Drospirenone-containing pills (Yaz, Yasmin) carry the highest relative risk among oral formulations, at approximately 6.3 per 10,000 woman-years according to an FDA safety communication [7].

Pandia prescribes drospirenone-containing pills. The clinical question is whether an asynchronous intake form can adequately screen for the constellation of VTE risk factors that the American College of Chest Physicians (ACCP) guidelines enumerate: Factor V Leiden, prothrombin G20210A mutation, antiphospholipid antibodies, family history of unprovoked VTE before age 50, obesity (BMI ≥30), and smoking [8]. Each factor is multiplicative, not additive. A woman with Factor V Leiden heterozygosity on a COC has a VTE risk approximately 20- to 30-fold above baseline [6].

Pandia does not require thrombophilia screening before prescribing. Neither do most in-person clinics, and ACOG does not recommend universal thrombophilia testing for contraceptive candidates [9]. But the difference is this: an in-person clinician can probe a vague family history ("my aunt had a blood clot, I think") in real time, order targeted labs, and make a judgment call. An asynchronous form cannot follow up on ambiguity. Dr. Kirtly Parker Jones, a reproductive endocrinologist at the University of Utah, has noted: "The family history question is only as good as the patient's knowledge of their own family, and most patients do not know their family's clotting history in clinical detail" [9].

Menopause Services: A Narrow Window

Pandia expanded into menopause care, offering estradiol patches, oral progesterone, and select topical estrogens. This addresses a documented gap. A 2023 survey published in Menopause found that only 20% of ob-gyn residency programs offered formal menopause training, leaving many clinicians uncomfortable prescribing HRT [10]. Telehealth platforms that connect patients with menopause-trained physicians can improve access.

The limitation is scope. The 2022 Hormone Therapy Position Statement from The North American Menopause Society (NAMS) recommends individualized therapy that may include transdermal estradiol, micronized progesterone, vaginal DHEA, ospemifene, low-dose vaginal estrogen, or testosterone for hypoactive sexual desire disorder [11]. Pandia's published formulary does not include testosterone therapy, vaginal DHEA (Intrarosa), or ospemifene (Osphena). For a patient with genitourinary syndrome of menopause (GSM) who has failed topical estrogen, the next evidence-based option (vaginal DHEA or ospemifene) is not available through Pandia.

Lab monitoring presents another concern. The Endocrine Society's 2019 guidelines on testosterone therapy in women recommend baseline and follow-up total testosterone levels, along with lipid panels and liver function tests for patients receiving systemic hormone therapy [12]. Pandia does not integrate lab ordering into its standard menopause workflow. A patient on estradiol patches without periodic estradiol level checks, CBC, or metabolic panel is receiving therapy without the monitoring infrastructure that guideline-concordant care requires.

What About Metabolic and Weight-Management Therapies?

Pandia does not offer GLP-1 receptor agonists (semaglutide, tirzepatide), testosterone replacement for men or women, or peptide therapies. For patients whose hormonal picture extends beyond contraception or menopause (metabolic syndrome, PCOS with insulin resistance, hypogonadism), the platform has no pathway.

This matters because hormonal contraception and metabolic health are not independent systems. A 2020 meta-analysis in The Journal of Clinical Endocrinology & Metabolism found that COC use was associated with a 19% increase in insulin resistance markers (HOMA-IR) compared to non-use, with the effect most pronounced in formulations containing androgenic progestins [13]. For a patient with borderline insulin resistance or prediabetes (fasting glucose 100-125 mg/dL), prescribing a COC without metabolic context could worsen glycemic trajectory. Pandia's intake form does not capture fasting glucose or HbA1c. It cannot.

A full-spectrum telehealth platform would cross-reference contraceptive choice with metabolic status, PCOS diagnosis, and BMI-related risk. That integration does not exist within Pandia's current model.

Pandia Health vs. Full-Spectrum Telehealth Alternatives

The telehealth contraception space has become crowded. Nurx, SimpleHealth, Favor, and Lemonaid all compete with Pandia. Each has limitations. But the distinguishing question is clinical depth, not convenience.

Dr. Eve Espey, a professor of obstetrics and gynecology at the University of New Mexico and past ACOG committee chair, stated in a 2022 commentary: "Convenience without clinical rigor is not access. True contraceptive access means the right method for the right patient, with appropriate screening and follow-up" [14].

Pandia's $25/consultation fee (without insurance) and free delivery model is accessible. The cost is lower than a typical office co-pay. But the clinical encounter is also thinner. A 2022 cross-sectional study in JAMA Network Open examined 12 direct-to-consumer contraceptive platforms and found that only 58% documented all CDC Medical Eligibility Criteria (MEC) Category 3 and 4 conditions during intake [15]. The study did not single out Pandia, but the finding applies to the asynchronous model broadly.

Full-spectrum telehealth alternatives that offer synchronous video consultations, integrated lab ordering, LARC referral networks, and broader formularies (including testosterone, GLP-1s, and metabolic panels) provide a more complete clinical picture. The trade-off is typically higher cost and longer wait times for appointments.

Geographic and Regulatory Constraints

Pandia Health is not available in all 50 states. Physician licensing requirements mean the platform can only operate where its clinicians hold active medical licenses. As of early 2026, Pandia lists availability in approximately 25 to 30 states. If you move or travel, your prescription continuity may be interrupted.

The Interstate Medical Licensure Compact has expanded multi-state practice for some telehealth providers, but contraceptive prescribing regulations vary by state [16]. Some states require an initial in-person visit before telehealth prescribing. Others restrict which controlled substances can be prescribed via telehealth. These are not Pandia-specific problems. They are structural barriers in U.S. telehealth, but they constrain what Pandia can deliver.

The Follow-Up Gap

Perhaps the most clinically significant limitation is follow-up cadence. ACOG recommends a return visit 3 months after initiating a new hormonal contraceptive to assess side effects, blood pressure, and adherence [1]. For menopause HRT, the Endocrine Society recommends reassessment at 3 months and then annually, with labs as clinically indicated [12].

Pandia's model is prescription-forward. Refills ship automatically. The platform does offer follow-up consultations, but they are patient-initiated, not system-triggered. There is no automated 3-month check-in, no prompted side-effect survey, no standing lab order at a partner lab. The patient must remember to seek follow-up. This passive model works for motivated, health-literate patients. For the broader population, it creates a monitoring gap that compounds over years of use.

A 2021 analysis in Obstetrics & Gynecology found that patients using asynchronous contraceptive platforms had 37% fewer follow-up encounters in the first year compared to patients receiving contraception through traditional clinic visits [3]. Fewer follow-ups meant delayed detection of side effects including breakthrough bleeding, mood changes, and hypertension.

Who Pandia Health Works For (and Who It Doesn't)

Pandia is a reasonable choice for healthy patients aged 18 to 35 with no cardiovascular risk factors, no family history of VTE, normal blood pressure, and a preference for oral contraceptives, the patch, or the ring. For this population, the convenience and cost savings are real, and the clinical risk of an asynchronous model is low.

Pandia is not the right fit for patients with migraine with aura (MEC Category 4 for CHCs), BMI ≥35, uncontrolled hypertension, personal or strong family history of VTE, PCOS with metabolic features, or complex menopausal symptoms requiring multi-drug titration. These patients need synchronous clinical encounters, integrated labs, and a broader formulary than Pandia provides.

The distinction is not about whether Pandia is "legit." It is licensed, employs board-certified physicians, and fills a genuine access gap. The distinction is about clinical completeness. A platform that covers 60% of the contraceptive formulary and 40% of the menopause formulary, without integrated labs or proactive follow-up, is a partial solution. Patients should understand what falls outside that partial coverage before they commit to it as their sole source of hormonal care.